Wall Street Analyst Initiated Agenus Inc. [AGEN]. What else is Wall St. saying


Agenus Inc. [NASDAQ: AGEN] traded at a high on 08/02/22, posting a 3.63 gain after which it closed the day’ session at $2.57. The company report on August 2, 2022 that Agenus to Participate at BTIG Biotechnology Conference.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference. Agenus will participate virtually and host one-on-one meetings with investors following its second quarter 2022 corporate update on the morning of August 9.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer and infections. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

The results of the trading session contributed to over 3803551 shares changing hands. Over the past one week, the price volatility of Agenus Inc. stands at 7.78% while the volatility over the past one month is 9.68%.

The market cap for AGEN stock reached $778.07 million, with 258.31 million shares outstanding and 242.97 million shares in the current float. Compared to the average trading volume of 5.18M shares, AGEN reached a trading volume of 3803551 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Agenus Inc. [AGEN]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2021. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Agenus Inc. stock. On October 28, 2016, analysts decreased their price target for AGEN shares from 10 to 5.

The Average True Range (ATR) for Agenus Inc. is set at 0.23, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 2.51. The Price to Book ratio for the last quarter was 42.83, with the Price to Cash per share for the same quarter was set at 0.87.

How has AGEN stock performed recently?

Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.19. With this latest performance, AGEN shares gained by 31.12% in over the last four-week period, additionally sinking by -6.88% over the last 6 months – not to mention a drop of -51.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 52.51, with the RSI for the last a single of trading hit 47.21, and the three-weeks RSI is set at 54.64 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 2.09, while it was recorded at 2.66 for the last single week of trading, and 2.73 for the last 200 days.

Agenus Inc. [AGEN]: Deeper insight into the fundamentals

Agenus Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.

Insider trade positions for Agenus Inc. [AGEN]

There are presently around $350 million, or 51.60% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: VANGUARD GROUP INC with ownership of 18,402,409, which is approximately 4.354% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 17,955,622 shares of the stock with an approximate value of $46.15 million in AGEN stocks shares; and STATE STREET CORP, currently with $45.64 million in AGEN stock with ownership of nearly -16.118% of the company’s market capitalization.

82 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 23,332,878 shares. Additionally, 85 investors decreased positions by around 21,722,868 shares, while 37 investors held positions by with 91,209,010 shares. The mentioned changes placed institutional holdings at 136,264,756 shares, according to the latest SEC report filing. AGEN stock had 30 new institutional investments in for a total of 16,662,260 shares, while 33 institutional investors sold positions of 5,322,512 shares during the same period.